Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors

NCT01034306 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT01034306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01034306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors
Lead sponsor
Can-Fite BioPharma
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
December 31, 2013
Enrollment
79 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis